Background: Studies investigating the effect of antibiotics on the pharmacokinetics of non-steroidal antiinflammatory drugs are few. Such interaction could be clinically significant in conditions like diabetic nephropathy. Objectives: To study the effect of amoxicillin and cefalexin on the pharmacokinetics of diclofenac sodium when taken concomitantly. Subjects and Methods: Eleven healthy subjects participated in this single dose cross-over study. Each volunteer randomly joined one of the three treatment groups and received a single dose of diclofenac sodium (50mg entericcoated tablet), diclofenac sodium + amoxicillin 500mg capsule, and diclofenac sodium + cefalexin 500mg capsule successively with one week washout interval. Blood samples were taken immediately before, at 30 minutes and at 1, 1.5, 2, 2.5, 3, 4 and 6 hours after drug administration and analyzed using high performance liquid chromatography (HPLC) system with ibuprofen as internal standard. Results: Diclofenac sodium produced a maximum concentration of 1.34 µg/ml with a half life of 0.5 hour and area under plasma concentration versus time curve up to 6 hours (AUC 0-6 ) of 1.24 µg.h/ml. Although the AUC 0-6 and maximum plasma concentration of diclofenac sodium increased by more than 20% after co-administration of amoxicillin, this increase is not statistically significant. Cefalexin, on the other hand, when given with diclofenac sodium significantly increased the AUC 0-6 and maximum plasma concentration of diclofenac by 51.9% and 68.5% respectively. Conclusion: Amoxicillin and cefalexin can change some of the pharmacokinetic parameters of diclofenac tablet when administered concomitantly and cefalexin did that to a greater extent. Such interaction must, therefore, be considered in conditions where diclofenac might be harmful.
[9,10] The subject of antibiotics affecting the kinetics of NSAIDs is much less investigated. Azithromycin and enrofloxacin were found to increase or decrease diclofenac and piroxicam concentrations. [11] [12] [13] The present study was, therefore, conducted to investigate the effect of two commonly used oral antibiotics; amoxicillin and cefalexin, on the pharmacokinetic parameters of diclofenac sodium.
SUBJECTS AND METHODS
This study was conducted at the College of Medicine, University of Basrah during the academic year 2012/2013 and its protocol was approved by the College Ethical Committee. Eleven (out of 12) adult subjects successfully completed a randomized, three-way, cross-over study. All were considered healthy based on medical history, physical examination, and routine laboratory investigations. Their mean ± SD of body mass index (BMI) was 22.53±2.38, age 22.73±3.44 years, weight 62.18±10.38 kg and height was 165.73±8.33 cm. All subjects gave their written informed consent to participate in the study. Subjects were 5 males and 6 females, non-smokers and without a history of alcohol or drug abuse. They did not take any other concomitant medications (including herbal remedies) for one week before as well as during the study. Patients with history of drug allergy, any associated disease and repeated drug use and those with any contraindication to the use of NSAIDs had been excluded. Each volunteer randomly joined one of the three treatment groups and received a single dose of diclofenac sodium (50mg entericcoated tablet), diclofenac sodium + amoxicillin 500mg capsule, and diclofenac sodium + cefalexin 500mg capsule successively, in a cross-over design, with one week washout interval in between. Drugs were administered with 150 ml water starting from 08.00 h after an overnight fast. Intake of light food was delayed for 3 h after drug administration. Peripheral venous blood samples were taken immediately before, at 30 minutes and at 1, 1.5, 2, 2.5, 3, 4 and 6 hours after drug administration. During each session, blood samples were collected in EDTA tubes and immediately centrifuged. Plasma was separated and frozen at −15°C until further analysis.
Determination of diclofenac sodium
Diclofenac sodium and ibuprofen pure powders were kindly supplied by SDI, Samara, Iraq. In a 10 ml test tube, 50 µl of internal standard D solution (containing ibuprofen 2.5 µg) were added to 0.5ml of plasma. Acidification with 1 ml of 1M orthophosphoric acid was followed by extraction with 5ml of a mixture of hexane and isopropyl alcohol (90:10); then centrifugation, recovery of 3 ml of the organic layer, evaporation to dryness and dissolution of the dry residue in 100µl of the mobile phase, immediately before injection. The apparatus was an Agilent HPLC system model 1200 (USA), with variable wavelength detector. Chromatographic separation was performed using a Zorbax Eclipse XBD-C18 column. The chromatographic parameters were: pH 3.5, temperature 25 ○ C, flow rate 1.5 ml/min, detection wavelength 276 nm. Quantitation was achieved by measurement of the peak height ratios of the drug to the internal standard. The intraday coefficient of variation (CV) of internal standard samples was 3.3% while the inter-day coefficient of variation was 8.5%. The lowest value on the calibration curve; the lower limit of quantitation, was 0.1 µg/ml. The method used for extraction of diclofenac from serum was similar to that described by Emami et al. [14] Differences between different parameters of each antibiotic group and that of diclofenac sodium was tested using paired t-test. A difference was considered statistically significant for p value of 0.05 and less.
RESULTS Figure-1 , shows the chromatogram of blank plasma with ibuprofen 2.5 mg/ml as internal standard (A). and blank plasma with diclofenac sodium at a concentration of 1 µg/ml and ibuprofen (B). Both compounds eluted as completely resolved peaks and no peak tailing was noticed enabling the use of peak height ratio in the calculation of the calibration curve. An optimum flow rate of 1.5 ml/min for the mobile phase resulted in the retention times of 5.3 min for diclofenac sodium and 6.3 min for ibuprofen. Diclofenac concentrations were plotted versus their respective time points to obtain a concentration-time curve from which the principal pharmacokinetic parameters were calculated. These include the area under the curve (AUC), maximal plasma concentration (C max ), time to achieve maximal plasma concentration, elimination half life and lag time.
Pharmacokinetic parameters of diclofenac sodium
The pharmacokinetic parameters of diclofenac sodium given alone as a single 50 mg entericcoated tablet to 10 healthy volunteers is described in (table-1) . Concomitant administration of amoxicillin with diclofenac sodium resulted in an increase in AUC 0-6 and C max of diclofenac sodium by 27.4% and 22.1%; and a decrease in T max , t 1/2 and lag time by 24.2%, 27.8% and 24.3% respectively. However, these changes are not statistically significant except the change in half-life (Tables-2 and 4) (figure-2). Cefalexin when given in combination with diclofenac sodium increased diclofenac sodium AUC 0-6 and C max by 51.9% and 68.5% respectively. This increase is statistically significant ( Table-3 ). The changes in diclofenac sodium T max , t 1/2 and lag time are not statistically significant when given with cefalexin (tables 3 and 4), (figure-2). and increased that of cephalosporins and tetracycline in different animal species.
[5-7], [15] Few studies investigated the effect of antibiotics on plasma concentration of NSAIDs with contradictory results. Kumar et al [13] found that enrofloxacin decreased the plasma concentration of diclofenac while Rahal et al [11] showed that the same antibiotic;
enrofloxacin, increased diclofenac plasma concentration. Therefore, the present study is an attempt to study the effect of two commonly used antibiotics; amoxicillin and cefalexin, on the pharmacokinetic parameters of diclofenac sodium. Changing the therapeutic level of diclofenac might have an important impact on the profile of its toxicity, particularly in diabetics with compromised renal function. The present study showed that both amoxicillin and cefalexin enhanced the C max and AUC 0-6 of diclofenac but cefalexin did that to a greater extent than amoxicillin. There are a number of speculations regarding the possible mechanism of this interaction. Such interaction could be at the level of the kidney where both drugs may compete for the same secretory mechanism in the renal tubules resulting in higher plasma concentration.
[2] Oh and Han [15] found that renal clearance of tetracycline was reduced by diclofenac and naproxen. Although the protein and tissue binding of amoxicillin and cefalexin are not high, displacement of a highly protein bound drug with high tissue affinity like diclofenac, is a possibility. [15] [16] [17] Interaction at the level of the liver is less likely because both antibiotics are actively secreted through the kidney. However, it occurred with ceftriaxone and diclofenac in the rabbit due to increased hepatic blood flow with consequent reduced hepatic clearance.
[6] It happened, sporadically, in some volunteers that diclofenac sodium could not be detected in the blood during the 6 hour period after ingestion of diclofenac sodium either alone or in combination with the antibiotics (a total of 3 volunteers). Those volunteers had been excluded from the final statistical analysis. Several explanations can be postulated. The volunteer might not have taken the diclofenac tablet; the absorption was delayed beyond the 6-hour-period, or the tablet that was taken might be defective. The first possibility was ruled out because one of these volunteers is directly related to this study. Malizia et al [18] found that azithromycin decreased the level of diclofenac in the first 3 hours and increased it later on. However, delayed absorption is a possibility that had not been ruled out in this study.
In conclusion, the pharmacokinetics of diclofenac could be changed by coadministration of antibiotics such as cefalexin and amoxicillin. Such interaction should be taken in consideration in conditions where diclofenac might be harmful.
